Co-targeting melanoma with BRAF/MEK and PI3-K inhibitors to overcome BRAF inhibitor- resistance provided further evidence showing that a combination targeted therapy is necessary for melanoma treatment 18-20. The gene discussed is BRAF; the disease is melanoma.